XML 25 R11.htm IDEA: XBRL DOCUMENT v3.6.0.2
Cash and Cash Equivalents and Fair Value of Financial Instruments
12 Months Ended
Dec. 31, 2016
Fair Value Disclosures [Abstract]  
Cash and Cash Equivalents and Fair Value of Financial Instruments
Cash and Cash Equivalents and Fair Value of Financial Instruments
Cash and cash equivalents include money market funds, which have original maturities of three months or less.  Due to the short duration to maturity, the carrying value of such financial instruments approximates the estimated fair value.
Cash and cash equivalents at December 31, 2016 and December 31, 2015 were as follows:
 
December 31, 2016
 
December 31, 2015
 
(In thousands)
Cash
$
54,488

 
$
72,103

Cash equivalents

 
10,114

Total cash and cash equivalents
$
54,488

 
$
82,217


Fair value hierarchy
The Company measures its financial instruments at fair value. The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy as they are valued primarily using quoted market prices utilizing market observable inputs. The Company's interest rate swap contracts and foreign currency contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. The Company's contingent consideration liability related to the Avantec acquisition is classified as Level 3 as valuation inputs are unobservable in the market and significant to the instrument’s valuation. During the year ended December 31, 2016, the Company paid $3.0 million for contingent consideration and recorded $0.2 million for accrued interest. Additionally, the Company determined the final payout amount for the remaining contingent consideration and reduced the liability from $3.0 million to $2.4 million. The reduction of the contingent liability resulted in a gain of $0.6 million which is disclosed within "Interest and other income (expense), net" capture of the Statement of Operations for the year ended December 31, 2016.
The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of December 31, 2016:
 
Level 1
 
Level 2
 
Level 3
 
Total
 
(In thousands)
Interest rate swap contracts
$

 
$
1,245

 
$

 
$
1,245

Total financial assets
$

 
$
1,245

 
$

 
$
1,245

Contingent consideration liability
$

 
$

 
$
2,400

 
$
2,400

Total financial liabilities
$

 
$

 
$
2,400

 
$
2,400


The significant unobservable inputs used in the fair value measurement of the contingent consideration classified as level 3 above are the achievement of booking targets and the discount rate. There have been no transfers between fair value measurement levels during the year ended December 31, 2016 and December 31, 2015.
The following table represents the fair value hierarchy of the Company’s financial assets measured at fair value as of December 31, 2015:
 
Level 1
 
Level 2
 
Level 3
 
Total
 
(In thousands)
Money market funds
$
10,114

 
$

 
$

 
$
10,114

Forward contracts

 
32

 

 
32

Total financial assets
$
10,114

 
$
32

 
$

 
$
10,146

Contingent consideration liability
$

 
$

 
$
5,823

 
$
5,823

Total financial Liabilities
$

 
$

 
$
5,823

 
$
5,823


Foreign Currency Risk Management
The Company operates in foreign countries, which expose it to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, the most significant of which is the British Pound and Euro. In order to manage foreign currency risk, at times the Company enters into foreign exchange forward contracts to mitigate risks associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities of our foreign subsidiaries.  In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. By working only with major banks and closely monitoring current market conditions, the Company seeks to limit the risk that counterparties to these contracts may be unable to perform. The foreign exchange forward contracts are measured at fair value and reported as other current assets or accrued liabilities on the Consolidated Balance Sheets. The derivative instruments the Company uses to hedge this exposure are not designated as hedges. Any gains or losses on the foreign exchange forward contracts are recognized in earnings as Other Income/Expense in the period incurred in the Consolidated Statements of Operations. The Company does not enter into derivative contracts for trading purposes.
At December 31, 2016, the Company had no outstanding foreign exchange forward contracts. The aggregate notional value of these outstanding foreign exchange contracts as of December 31, 2015 was $0.4 million.
Interest Rate Swap Contracts
The Company uses interest rate swap agreements to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company's interest rate swaps, which are designated as cash flow hedges, involve the receipt of variable amounts from counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company does not hold or issue any derivative financial instruments for speculative trading purposes.
During 2016, the Company entered into an interest rate swap agreement with a combined notional amount of $100.0 million with one counter-party that is effective beginning on June 30, 2016 and maturing on April 30, 2019. The swap agreement requires the Company to pay a fixed rate of 0.8% and provides that the Company will receive a variable rate based on the one month LIBOR rate subject to LIBOR floor of 0.0%. Amounts payable by or due to the Company will be net settled with the respective counter-party on the last business day of each month, commencing July 31, 2016.
The fair value of the interest rate swap agreements at December 31, 2016 was $1.2 million. There were no amounts reclassified into current earnings due to ineffectiveness during the periods presented.